A Phase 3 interventional study of Cilostazol and Aspirin in Coronary Artery Disease, sponsored by Seoul National University Bundang Hospital. Completed at 1 site in Korea, Republic of. Open to participants aged 30 Years to 80 Years. Per ClinicalTrials.gov, last updated 2017-10-09.
Sponsored by Seoul National University Bundang Hospital · Phase 3, Interventional, and Treatment
This is a prospective interventional study to assess the effect of cilostazol compared with aspirin in Korean T2DM patients with atherosclerosis.
Type 2 diabetes has been increased exponentially, arousing serious economic, social and health repercussions. Also, macrovascular complications of diabetes such as myocardial infarct or stroke have been increased. Individuals with diabetes have a greater risk of cardiovascular disease (CVD), approximately two to four times than that of those without diabetes. Currently, the U.S. Food and Drug Administration requires demonstration that new anti-hyperglycemic agents do not increase CV risk. The comprehensive and multifactorial management in type 2 diabetes, which includes control of hypertension, dyslipidemia and obesity, is known to significantly reduce the risk of CVD as shown in Steno-2 study. However, most anti-diabetic agents currently used in clinical practice do not seem to provide enough CV protection.
This is a prospective interventional study to assess the effect of cilostazol compared with aspirin in Korean T2DM patients with atherosclerosis. T2DM patients who have coronary artery stenosis by MDCT at least 3 months prior to this investigation will be enrolled.
Considering drop out due to adverse events or follow up loss, sufficient patients will be enrolled. Their medical record will be reviewed and relevant clinical and laboratory findings will be collected.
Cardiac computed tomography (CT) was introduced in the early 1990s. However, electron-beam CT (EBCT) only provided information on simple coronary artery calcium score (CAC). Recently, MDCT has been introduced, which can evaluate coronary arteries comprehensively. MDCT images can provide measurements of CAC, the degree of stenosis, and the characteristics of plaque including its potential vulnerability. These findings of MDCT have been reported to be in good agreement with intravascular ultrasound.
All scans are analyzed independently by two experienced investigators using a 3D workstation, who are blinded to the clinical information (Brilliance; Philips Medical Systems). After independent evaluations are made, a consensus interpretation is arrived at regarding the final MDCT diagnosis. Each lesion is identified using a multiplanar reconstruction technique and maximum intensity projection of the short axis, in two-chamber and four-chamber views. Image quality is evaluated on a per-segment basis and classified. Plaque characteristics on a per-segment basis are analyzed according to the modified American Heart Association classification.
5,598 studies on the registry are indexed under Coronary Artery Disease; 957 are open to participants now.
This study's enrollment of 100 is below the median of 124 across 3,436 interventional studies indexed under Coronary Artery Disease.
Browse Coronary Artery Disease studies →Seoul National University Bundang Hospital is the lead sponsor of 368 studies on the registry; 55 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Cilostazol 100-200 mg qd
Drug: Cilostazol
Asprin 100mg qd for active comparator
Drug: Aspirin
Pletaal as an active drug
Also known as: Pletaal
Aspirin as an active comparator
Coronary artery stenosis
Severity of coronary artery stenosis (%)
Time frame: one year
Plaque characteristics
Noncalified plaque
Time frame: one year
Plaque characteristics
Mixed plaque
Time frame: one year
Plaque characteristics
Calcified plaque
Time frame: one year
Multivessel involvement
Multivessel involvement in coronary arteries
Time frame: one year
Main vessel involvement
Left main and/or proximal LAD stenosis
Time frame: one year
Coronary artery calcium (CAC) score
Agatston score for CAC
Time frame: one year
Glucose homeostasis
Changes in HbA1c
Time frame: one year
Glucose homeostasis
Changes in fasting glucose concentration
Time frame: one year
Lipid metabolism
Changes in TG concentration
Time frame: one year
Lipid metabolism
Changes in HDL-concentration concentration
Time frame: one year
Bleeding risk
Any type of bleeding
Time frame: one year
Headache
Any type of headache
Time frame: one year
Heart rate
Frequence of heart beat per min
Time frame: one year
This study is completed, as verified in Oct 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Seoul National University Bundang Hospital